Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...
First orphan designation ever granted to a condensate-modulating therapeuticBuilds on recent IND opening for DPTX3186, a ...
Cizzle Bio Inc. founder and CEO Bill Behnke moderated a high-profile panel at the 2025 Association for Value-Based Cancer ...
Jeff Bartoszewicz and Stacy Hampton join us on The Morning Blend to discuss a walk in honor of the fight against stomach ...
ACT: The MATTERHORN trial showed a 22% reduction in the risk of death with the Imfinzi regimen. How significant is this ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
If you naturally associate stomach cancer with brutally painful stomachaches, you're not the only one. And yet, stomachaches are not typically a sign of this rare form of cancer at any point in its ...
Globally, stomach cancer is on the rise in young people, but new research shows that three-quarters of future cases could be prevented by screening for and treating a common bacterial infection: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback